Condition: Prostate Cancer · Biochemical Recurrence · Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
To evaluate the efficacy and safety of rezvilutamide in combination with androgen deprivation therapy(ADT) and standard salvage radiation therapy(SRT) or rezvilutamide in combination with ADT in prostate cancer patients with biochemical recurrence of prostate-specific antigen(PSA) persistence after radical prostatectomy(RP).
This description comes directly from the study's public registry record.
Hongqian Guo, phD · +86-13605171690 · dr.ghq@nju.edu.cn
Shun Zhang, MD · +86-15050589789 · explorershun@126.com
Always discuss trial participation with your own doctor first.
| The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Nanjing, Jiangsu, China | Recruiting |
| JiangSu Cancer Hospital | Nanjing, Jiangsu, China | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05753566